Clinical Trials in Cleveland

Showing 5741-5760 of 15,050 trials

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

NCT03181789

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of two HIV-1 pDNA vaccines: p24CE1/2 pDNA and p55\^gag pDNA administered with IL-12 pDNA adjuvant, given by intramuscular (IM) injection with electroporation (EP), in healthy, HIV-uninfected adults.

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)56 participantsStarted Oct 2017

San Francisco, California, United States • Decatur, Georgia, United States • Cleveland, Ohio, United States

TERMINATEDPhase 3< 1 mile

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

NCT04844749

To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.

Metastatic Castration-resistant Prostate CancerAndrogen Resistant Prostatic Cancer

Veru Inc.105 participantsStarted Jun 2021

Anchorage, Alaska, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +37 more locations

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Find Trials by Condition in Cleveland

PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

ILLUMENATE Pivotal Post-Approval Study (PAS)

The Acute Burn ResUscitation Multicenter Prospective Trial

Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Omnibond vs Dermabond

Pleconaril Enteroviral Sepsis Syndrome

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Actuate 1901: 9-ING-41 in Myelofibrosis

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria